Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Menzin

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Pharmacoeconomics|December 9, 1993
Methodological issues in economic assessments of new therapies. The case of colony-stimulating factorsM Drummond, J Menzin, G Oster
Thrombosis and Haemostasis|February 10, 2012
Factors associated with failure to correct the international normalised ratio following fresh frozen plasma administration among patients treated for warfarin-related major bleeding. An analysis of electronic health recordsJ Menzin, L A White, M Friedman, et al.
European Journal of Cancer Care|September 13, 2012
Quality-adjusted life years in cancer: pros, cons, and alternativesR M Woodward, J Menzin, P J Neumann
Pharmacoeconomics|July 7, 1992
Economic evaluation of oral ofloxacin versus standard parenteral therapy in the treatment of pneumoniaJ Menzin, D M Huse, R Richner, et al.
Pharmacoeconomics|December 9, 1993
Pharmacoeconomic evaluation of lenograstim. Conclusions and future directionsJ Menzin, G Oster, V Cour-Chabernaud, et al.
Pharmacoeconomics|March 17, 2001
A general model of the effects of sleep medications on the risk and cost of motor vehicle accidents and its application to FranceJ Menzin, K M Lang, P Levy, et al.
Pharmacoeconomics|December 9, 1993
Overview of the lenograstim pharmacoeconomics programmeG Oster, J Menzin, D Richard, et al.
The Annals of Pharmacotherapy|August 4, 2001
Cost-effectiveness results from the US Carvedilol Heart Failure Trials ProgramM Vera-Llonch, J Menzin, R E Richner, et al.
Diabetes Care|February 24, 2001
Potential short-term economic benefits of improved glycemic control: a managed care perspectiveJ Menzin, C Langley-Hawthorne, M Friedman, et al.
The Annals of Pharmacotherapy|February 1, 1994
Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluationJ Menzin, R Richner, D Huse, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Pharmacoeconomics|December 9, 1993
Methodological issues in economic assessments of new therapies. The case of colony-stimulating factorsM Drummond, J Menzin, G Oster
Thrombosis and Haemostasis|February 10, 2012
Factors associated with failure to correct the international normalised ratio following fresh frozen plasma administration among patients treated for warfarin-related major bleeding. An analysis of electronic health recordsJ Menzin, L A White, M Friedman, et al.
European Journal of Cancer Care|September 13, 2012
Quality-adjusted life years in cancer: pros, cons, and alternativesR M Woodward, J Menzin, P J Neumann
Pharmacoeconomics|July 7, 1992
Economic evaluation of oral ofloxacin versus standard parenteral therapy in the treatment of pneumoniaJ Menzin, D M Huse, R Richner, et al.
Pharmacoeconomics|December 9, 1993
Pharmacoeconomic evaluation of lenograstim. Conclusions and future directionsJ Menzin, G Oster, V Cour-Chabernaud, et al.
Pharmacoeconomics|March 17, 2001
A general model of the effects of sleep medications on the risk and cost of motor vehicle accidents and its application to FranceJ Menzin, K M Lang, P Levy, et al.
Pharmacoeconomics|December 9, 1993
Overview of the lenograstim pharmacoeconomics programmeG Oster, J Menzin, D Richard, et al.
The Annals of Pharmacotherapy|August 4, 2001
Cost-effectiveness results from the US Carvedilol Heart Failure Trials ProgramM Vera-Llonch, J Menzin, R E Richner, et al.
Diabetes Care|February 24, 2001
Potential short-term economic benefits of improved glycemic control: a managed care perspectiveJ Menzin, C Langley-Hawthorne, M Friedman, et al.
The Annals of Pharmacotherapy|February 1, 1994
Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluationJ Menzin, R Richner, D Huse, et al.
Pageof 3